Tenaya Therapeutics announced a research collaboration with Alnylam Pharmaceuticals that became effective on March 4, 2026. The agreement provides for an upfront payment of up to $10 million, additional research funding, and the potential for up to $1.13 billion in milestone payments if therapeutics derived from the partnership reach commercialization.
Under the terms, Tenaya will validate up to 15 gene targets over a two‑year period using its modality‑agnostic target identification and validation platform. Alnylam will assume responsibility for the development and commercialization of any resulting therapeutics, allowing Tenaya to focus on target discovery while leveraging Alnylam’s RNAi platform and manufacturing capabilities.
The collaboration comes at a time when Tenaya’s cash runway was a concern. As of June 2025, the company had $72 million in cash and a burn of $78 million over the preceding year, giving it roughly 11 months of runway. The upfront payment and research funding provide immediate liquidity, while the milestone upside offers a long‑term capital source that could reduce the need for future equity raises.
Alnylam’s cardiovascular portfolio, which includes the marketed therapy Amvuttra, is expanding with a $250 million investment in RNAi manufacturing. The partnership adds new genetic targets to Alnylam’s pipeline and aligns with its strategy to broaden its RNAi therapeutic reach into cardiovascular disease.
Investors reacted positively to the announcement, citing the significant financial upside and the de‑risking of Tenaya’s pipeline. The potential $1.13 billion in milestone payments and the transfer of development costs to Alnylam address Tenaya’s cash runway concerns and enhance its strategic positioning.
Faraz Ali, CEO of Tenaya, said, "By combining our modality agnostic target identification and validation capabilities with Alnylam's leadership in RNA interference therapeutics, we have an opportunity to advance candidates for novel genetic targets with the potential to create transformational medicines for patients with heart disease."
The partnership positions Tenaya to accelerate its gene therapy programs, including clinical‑stage candidates TN‑201 and TN‑401, while providing a substantial financial boost. For Alnylam, the deal expands its cardiovascular pipeline and leverages its RNAi manufacturing expansion, creating a strategic win for both companies.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.